Eyemaxx Real Estate AG

  • WKN: A0V9L9
  • ISIN: DE000A0V9L94
  • Land: Deutschland

Nachricht vom 24.06.2019 | 09:00

Eyemaxx sells 'Vivaldi Höfe' project in Schönefeld

DGAP-News: Eyemaxx Real Estate AG / Key word(s): Disposal/Miscellaneous

24.06.2019 / 09:00
The issuer is solely responsible for the content of this announcement.


Eyemaxx sells "Vivaldi Höfe" project in Schönefeld

Aschaffenburg, 24 June 2019 - Eyemaxx Real Estate AG (General Standard; ISIN: DE000A0V9L94; "Eyemaxx") has sold the "Vivaldi-Höfe" project in Berlin-Schönefeld to a renowned Berlin-based real estate company. The buyer takes over the entire project including the further implementation as well as the plot of land of around 73,000 m² east of the centre of Schönefeld, which Eyemaxx had acquired in Summer 2017. It was agreed not to disclose the purchase price.

The "Vivaldi Höfe" are the second project that Eyemaxx launched in Schönefeld. The large-scale project "Sonnenhöfe" on a plot of around 51,000 m², also in Schönefold, is carried out by Eyemaxx in cooperation with DIE Deutsche Immobilien Entwicklungs AG (DIEAG).

Dr. Michael Müller, CEO of Eyemaxx Real Estate AG: "The fact we can completely sell the entire Vivaldi Höfe project to a renowned German real estate company underpins the quality of the project. It also confirms the excellent location. We seized the opportunity to sell because we received an excellent offer. We will use the inflow of funds for the implementation of our well-filled pipeline and the launch of new, attractive projects."
 

About Eyemaxx Real Estate AG

Eyemaxx Real Estate AG is a real estate company with a long-standing successful track record, focussing on residential properties in Germany and Austria. In addition, Eyemaxx also realises commercial properties in central Europe. In the company's recent past its corporate strategy has also included hotels and serviced apartments as well as developing urban districts in Germany.

Eyemaxx' business activities take a dual-pronged approach. These include high-margin projects and also the continued expansion of its stocks of let commercial properties, which generate ongoing rental income and thus constant cash flows. In so doing, Eyemaxx uses the expertise offered by its experienced management team together with a strong team of real estate professionals, and also a well-established and broad network which opens up additional access to attractive properties and projects. As a result, the current project pipeline has been grown to total around one billion euros.

Shares of Eyemaxx Real Estate AG are listed in the General Standard of Frankfurt Stock Exchange and in the direct market plus on Vienna Stock Exchange. The company has also issued several bonds, which are also listed on the stock exchange.

You can find more information at www.eyemaxx.com
 

Contact

Investor Relations/Financial Press
Axel Mühlhaus, Peggy Kropmanns
edicto GmbH
Tel.: +49 69 905505-52
E-mail: eyemaxx@edicto.de



24.06.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

Anleihe im Fokus

Deutsche Rohstoff
"Anleihe - Jetzt zeichnen!"

- Emissionsvolumen: bis zu 100 Mio. EUR
- Zeichnungsfrist: 11.11. bis 04.12.2019
- ISIN: DE000A2YN3Q8 / WKN: A2YN3Q
- Börsenesegment: Börse Frankfurt, Open Market (Quotation Board)
- Stückelung / Emissionspreis: 1.000 EUR/ 100%
- Zinssatz (Kupon): 5,25 %
- Laufzeit: 5 Jahre
- Fälligkeit: 5 Jahre / 6.12.2024 (vorbehaltliche vorzeitige Rückzahlung gemäß Anleihebedingungen)
- Zinszahlung: Angebot an Inhaber der 5,625 % Schuldverschreibung 2016/2021 (WKN A2AA05, ISIN DE000A2AA055) diese in die neue Anleihe zu tauschen
- Umtauschfrist: 11.11.2019 – 29.11.2019 (18.00 Uhr)

GBC-Fokusbox

Expedeon AG mit attraktiver Produktpipeline

Durch die konsequente Fortsetzung der „Grow, Buy & Build“-Strategie hat die im Bereich der Entwicklung und Vermarktung von DNA-Technologien, Proteomik- und Antikörper-Konjugations-Anwendungen tätige Expedeon AG das Umsatzniveau angehoben und auf operativer Ergebnisebene zugleich den Break-Even nachhaltig überschritten. Für die kommenden Perioden ist der Ausbau der Umsatzerlöse mit den bestehenden Produkten geplant. Darüber hinaus verfügt die Expedeon AG über eine attraktive Produktpipeline mit hohem Umsatzpotenzial. Unser Kursziel liegt bei 3,20 € je Aktie. Das Rating lautet KAUFEN.

News im Fokus

Henkel AG & Co. KGaA: Henkel bestätigt Ausblick für das Geschäftsjahr 2019

14. November 2019, 07:30

Aktueller Webcast

EQS Group AG

Conference Call zu den Neunmonatszahlen 2019

15. November 2019

Aktuelle Research-Studie

SMT Scharf AG

Original-Research: SMT Scharf AG (von Montega AG): Kaufen

14. November 2019